FDA
approval
· 2023-08-02
FDA Approved: PREVYMIS — Supplemental Application (Merck Sharp & Dohme LLC)
Summary
The FDA approved a supplemental application for Prevymis (letermovir) submitted by Merck Sharp & Dohme LLC.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for PREVYMIS (LETERMOVIR)